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BACKGROUND: Previous studies suggest that prenatal exposure to phthalates, ubiquitous synthetic chemicals, may adversely affect neurodevelopment.
However, data are limited on how phthalates affect cognition, executive function, and behavioral function into adolescence.
OBJECTIVE:We aimed to investigate associations of prenatal phthalate exposure with neurodevelopment in childhood and adolescence in the Center
for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) study.
METHODS:We examined associations between maternal urinary phthalate metabolite concentrations measured twice during pregnancy and a range of
neurodevelopmental outcomes from ages 7 through 16 y in the CHAMACOS birth cohort (n=334). We used age-specific linear regression models
and generalized estimating equation models to assess longitudinal effects and examined differences by sex.
RESULTS: Phthalate metabolites were detected in 88%–100% of samples, depending on the metabolite. Associations of phthalates with neurodevelop-
mental outcomes were largely null with some noteworthy patterns. Higher prenatal concentrations of metabolites of low-molecular weight phthalates
(RLMW) were associated with more self-reported hyperactivity [b=0:8, 95% confidence interval (CI): 0.1, 1.4 per 2-fold increase in RLMW phtha-
lates], attention problems (b=1:5, 95% CI: 0.7, 2.2), and anxiety (b=0:9, 95% CI: 0.0, 1.8) at age 16. We observed sex-specific differences for the
sums of high-molecular-weight and di(2-ethylhexyl) metabolites and cognitive outcomes (e.g., b for Full-Scale IQ for boys= − 1:9, 95% CI: −4:1,
0.3 and −1:7, 95% CI: −3:8, 0.3, respectively; b for girls = 1:8, 95% CI: 0.1, 3.4 and 1.6, 95% CI: 0.0, 3.2, respectively; p-int = 0:01 for both).
CONCLUSION: We found predominantly null associations of prenatal phthalates with neurodevelopment in CHAMACOS, and weak associations of
RLMW phthalates with internalizing and externalizing behaviors in adolescence. No previous studies have examined associations of prenatal phthal-
ate exposure with neurodevelopment into adolescence, an important time for manifestations of effects. https://doi.org/10.1289/EHP5165
Introduction
Phthalates are a group of chemicals used in multiple consumer
products (Hauser and Calafat 2005). Low-molecular-weight
(LMW) phthalates are used in fragrances, cosmetics, and sham-
poos (ATSDR 1995, 2001; Harley et al. 2017), and personal care
products appear to be a primary source of exposure (Duty et al.
2005; Ejaredar et al. 2015). High-molecular-weight (HMW)phtha-
lates are common plasticizers in products such as food packaging,
building materials, medical devices, and toys (Ejaredar et al. 2015;
Harley et al. 2017). Phthalates are not covalently bound to the plas-
tics that they soften and can easily leach into the environment
(Braun et al. 2013; Meeker et al. 2009). Exposure to phthalates is
ubiquitous in the U.S. population (Chopra et al. 2014) and occurs
via ingestion, inhalation, and dermal absorption (Adibi et al. 2003;
Rudel et al. 2003). A recent examination of five cycles of the
National Health and Nutrition Examination Survey (NHANES)
found that 10 different phthalate metabolites were detected in
>70% of participants between 2001 and 2010 (Zota et al. 2014).
Although phthalates have short half-lives in the body and are
rapidly excreted (ATSDR 1995, 2001, 2002; Meeker et al. 2009),
humans are chronically exposed from common consumer goods,
including plastics, personal care products, and food packaging.
Phthalates are endocrine disrupting chemicals (EDCs) that cross
the placenta, exposing the developing fetus (Silva et al. 2004;
Wittassek et al. 2009). The Chronic Hazard Advisory Panel of
the U.S. Consumer Product Safety Commission identified fetal
development as the most vulnerable target of toxicity for phtha-
lates (Lioy et al. 2015), and the nervous system may be particu-
larly susceptible due to rapid brain development during the
prenatal period. Animal and epidemiologic studies have shown
that neurotoxic effects of phthalates may be mediated by antian-
drogenic activity (Borch et al. 2006; Weiss 2012), alterations in
thyroid function (Boas et al. 2010; Gao et al. 2017), and disrup-
tion of brain dopaminergic activity (Bellinger 2013; Tanida et al.
2009).
Several epidemiological studies have evaluated associations
between prenatal phthalate exposure and neurodevelopmental
outcomes among children followed up to age 10 (Braun et al.
2014, 2017; Engel et al. 2010; Factor-Litvak et al. 2014; Gascon
et al. 2015; Kobrosly et al. 2014; Lien et al. 2015; Miodovnik
et al. 2011; Shin et al. 2018; Whyatt et al. 2012), with inconsis-
tent findings that vary by phthalate metabolite and child sex
(Braun et al. 2013). Although previous studies have reported
associations of prenatal urinary phthalate concentrations with
poorer cognition (Factor-Litvak et al. 2014), social cognition
(Miodovnik et al. 2011), and executive function (Engel et al.
2010) and more internalizing and externalizing behaviors (Engel
et al. 2010; Kobrosly et al. 2014; Lien et al. 2015; Whyatt et al.
2012), others have found associations with improved cognitive
performance (Braun et al. 2017) or null associations with social
cognition outcomes (Braun et al. 2014; Shin et al. 2018).
To our knowledge, no studies have examined the associations of
prenatal phthalate exposure with neurodevelopment measured lon-
gitudinally during childhood and into adolescence—information
that is important for evaluating the potential long-term impact of
these chemicals.We examined associations of prenatal phthalate ex-
posure with cognition, executive function, and behavior outcomes
assessed from ages 7 through 16 y in the Center for the Health
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Assessment of Mother and Children of Salinas (CHAMACOS)
birth cohort study. We hypothesized that higher prenatal phthalate
concentrationswould be associated with adverse neurodevelopment
during childhood and adolescence.
Methods
Study Population
CHAMACOS is a longitudinal birth cohort study examining the
health effects of prenatal and early life environmental exposures
amongMexican-American children in California’s Salinas Valley.
Subject recruitment and procedures for CHAMACOS have been
described elsewhere (Eskenazi et al. 2004, 2006). Briefly, eligible
pregnant women (i.e., ≥18 y old, <20 wk gestation, Spanish- or
English-speaking, qualified for low-income health insurance, and
planning to deliver at the county hospital) were recruited in com-
munity clinics between September 1999 and December 2000. Of
the 601 women initially enrolled, 527 (88%) remained in the study
and delivered a live-born singleton.
We conducted interviews with mothers at two prenatal study
visits (median= 13 and 26 wk gestation), shortly after delivery,
and when children were age 6 months, and 1, 2, 3.5, 5, 7, 9, 10.5,
12, 14, and 16 y. We also assessed CHAMACOS children’s
growth and development from ages 6 months to 16 y. We re-
stricted current analyses to children born to mothers with meas-
ures of prenatal urinary phthalate metabolites who completed at
least one neurodevelopmental assessment at age 7 (n=322), 9
(n=319), 10.5 (n=307), 12 (n=322), 14 (n=312), or 16 y
(n=300). In total, 334 children (56% of the initial cohort) had
prenatal phthalate data and completed at least one assessment
included in these analyses (total sample size exceeds sample size
at any individual time point because some participants only com-
pleted tests at one time point; 334 unique participants provided
usable data from at least one visit).
The University of California Berkeley Committee for the
Protection of Human Subjects approved all study activities, and
we obtained written informed consent from all mothers. We also
obtained child verbal assent at age 7, 9, and 10.5 y, and child
written assent at age 12, 14, and 16 y. The Centers for Disease
Control and Prevention (CDC) deferred to the University of
California Berkeley IRB as the IRB of record.
Neurodevelopmental Outcomes
Bilingual, bicultural psychometricians, trained and supervised by
a clinical neuropsychologist, administered neuropsychological
tests and computer-based tasks in the child’s dominant language
in a quiet room free from distraction. We obtained additional in-
formation on children’s behavior across multiple settings with
rating scales administered to the parent at all study visits (7, 9,
10.5, 12, 14 and 16 y), the teacher at the 7-y visit, and the child
(self-report) at the 10.5-, 14-, and 16-y visits. Outlined below are
the instruments we used to assess cognition, executive function,
social cognition, and behavior in CHAMACOS children.
Executive Function
Behavior Rating Inventory of Executive Function (BRIEF)
(Gioia et al. 2000). Parents of CHAMACOS children completed
the BRIEF when their children were age 7, 9, and 12 y. Teachers
completed the BRIEF when children were 7 y old. We examined
age- and sex-standardized scores (T-scores; M=50, SD=10)
across two indices (the Behavioral Regulation Index and the
Metacognition Index) and one summary score (Global Executive
Composite).
NEPSY tower (Korkman et al. 1998). At age 9, children com-
pleted the NEPSY tower, which assesses planning, monitoring,
self-regulation, and problem solving and yields a single scaled
score (M=10, SD=3).
Wisconsin Card Sort Task-64: Computer version 2 – research
edition (WCST) (Heaton 2000). At ages 9 and 12 y, children
completed the WCST, a computerized test that measures skills
around strategic planning, ability to shift cognitive strategies, and
impulse control. We examined T-scores for errors and persevera-
tive errors (M=50, SD=10).
Cognition
Weschler Intelligence Scale for Children, fourth edition (WISC-IV)
(Weschler 2003). Study staff administered the WISC-IV at the 7-
and 10.5-y study visits. Children were administered the WISC-IV
in English (33.3% of participants) or Spanish (66.7% of partici-
pants) at age 7 y. All children were tested in English at age 10.5 y.
We calculated scores for Full-Scale IQ (FSIQ) and four subscales:
Verbal Comprehension (VCIQ), Perceptual Reasoning (PRIQ),
Working Memory (WMIQ), and Processing Speed (PSIQ). We
standardized scores against U.S. population-based norms for
English- and Spanish-speaking children (M=100, SD=15).
Social Cognition
Evaluación neuropsicológica del niño (ENI) (Matute et al.
2007). Children completed the ENI at age 9 y. In this test, chil-
dren were shown eight different photographs and scored on how
well they identified the mental state of others (e.g., happy, sad,
angry, scared). Participants received a score of 1 for correctly
identifying the expression and a score of 0 for incorrectly identi-
fying the expression (maximum=8 points).
NEPSY-II Affect Recognition subtest (Korkman et al. 2007).
Children completed the NEPSY-II Affect Recognition at age
12 y. In this test, children had to: a) identify whether two photo-
graphs depicted faces with the same affect; b) select two faces
with the same affect from three to four photographs; c) select one
of four faces that depicted the same affect as the face at the top of
the page; and d) view a photograph of a face briefly and select
two faces that depicted the same affect as the face previously
viewed. Participants received a score of 1 for correctly identify-
ing the expression and a score of 0 for incorrectly identifying the
expression (maximum=35 points).
Social Responsiveness Scale, version 2 (SRS-2) (Constantino
and Gruber 2012). At the 14-y visit, parents completed the SRS-
2, a 65-item rating scale developed to assess quantitative traits
related to Autism Spectrum Disorder (ASD) in population-based
samples (Constantino and Gruber 2012). Parents were asked the
frequency that their child exhibited specific behaviors, such as
avoiding social behavior with peers or adults, over the previous
6 months (1= not true, 2 = sometimes true, 3= often true, and
4= almost always true), and we computed sex-standardized SRS
total T-scores (M=50, SD=10).
Attention and Behavior
Behavior Assessment System for Children, second edition (BASC-
2) and Self-Report of Personality (SRP) (Reynolds and Kamphaus
2004). Parents completed the BASC-2 when children were age 7,
10.5, 14, and 16 y. Teachers completed the BASC-2 when children
were 7 y old. Children completed specific scales of the BASC-2
Self-Report of Personality (SRP) at 10.5 and 14 years of age and
completed a full SRP at 16 years of age. We examined parent- and
teacher-reported scores from four individual scales (hyperactivity,
attention problems, depression, and anxiety) and two composite
scales (internalizing and externalizing problems). We examined
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self-reported scores for the internalizing problems composite scale
(there was no externalizing composite score for the SRP) and the
hyperactivity, attention problems, depression, and anxiety sub-
scales. BASC-2 data were examined as age- and sex-standardized
T-scores (M=50, SD=10).
Conners’ Attention Deficit Hyperactivity Disorder (ADHD)/
DSM-IV Scales, parent versions (CADS) (Conners 2001). Parents
completed the CADS when children were ages 7, 9, and 12 y old.
Teachers completed the CADS at the 7-y study visit. We computed
age- and sex-standardized T-scores for the four CADS subscales
(Conners’ ADHD index, and DSM-IV-based inattentive, hyperac-
tive/impulsive subscales, and total ADHD) (M=50, SD=10).
Conners’ Continuous Performance Test, version 5 (CPT II)
(Conners and MHS Staff 2000). At 9 and 12 years of age, chil-
dren completed the CPT-II, a computerized test that assesses hit
rate, accuracy, and impulse control. We examined sex- and age-
standardized T-scores (M=50, SD=10) for errors of commis-
sion (false positives), errors of omission (false negatives),
and continuous ADHD Confidence Index score. The ADHD
Confidence Index score indicates the probability that children
are correctly classified as having clinical ADHD.
Phthalate Exposure Assessment
Mothers provided spot urine samples in polypropylene containers
at each of the two prenatal study visits (median= 13 and 26wk ges-
tation) (n=590). After collection, study staff aliquoted urine into
glass vials and stored them at −80C until shipment on dry ice to
the CDC for analysis. Urine samples were analyzed with online
solid phase extraction–isotope-dilution high-performance liquid
chromatography–electrospray ionization-tandem mass spectrome-
try (Silva et al. 2007) to quantify concentrations of 11 phthalate
Table 1. Sociodemographic characteristics [n (%) or median (P25–P75)] of live-born singletons from the initial CHAMACOS mother–child cohort (n=527)
and study participants with prenatal urinary phthalate metabolites who completed at least one of the neurobehavioral assessments at ages 7 (n=322).a
Characteristic
Live-born singletons n (%) or
Median (P25–P75)
Children with prenatal phthalates and
at least one assessment at 7-y visit N (%)
or Median (P25–P75)
Maternal/household characteristics
Age at enrollment (y) 25 (22–29) 25.5 (22–29)
Education
≤6th grade 228 (43.3) 142 (44.1)
7th–12th grade 192 (36.4) 110 (34.2)
Completed high school 107 (20.3) 70 (21.7)
Receptive vocabulary (PPVT score) at 9-y visit 98 (80–108)
Missing (n)b — 23
Country of birth
Mexico 444 (84.3) 277 (86.0)
Other 83 (15.8) 45 (14.0)
Years in U.S.
≤5 270 (51.2) 151 (46.9)
6–10 115 (21.8) 84 (26.1)
≥11 142 (27.0) 88 (27.0)
Parity
0 180 (34.2) 102 (31.7)
≥1 347 (65.8) 220 (68.3)
Smoking during pregnancy
No 496 (94.1) 309 (96.0)
Yes 31 (5.9) 13 (4.0)
Maternal depression at 9-year visit (≥16 CES-D score)
No 225 (42.7) 233 (72.4)
Yes 78 (14.8) 81 (25.1)
Missing (n)b 224 (42.5) 8 (2.5)
Household income at 10.5-year visit
At or below poverty level 242 (45.9) 225 (69.9)
Above poverty level 95 (18.0) 97 (30.1)
Missing (n)b 190 (36.1) 0 (0.0)
Child characteristics
Child’s sex
Boy 263 (49.9) 153 (47.5)
Girl 264 (50.1) 169 (52.5)
Birth weight (grams) 3,440 (3,155–3,780) 3,437.5 (3,170–3,785)
Gestational age at delivery (wk) 39 (38–40) 39 (38–40)
Breastfeeding duration (months)
≤6 311 (59.0) 163 (50.6)
>6 205 (38.9) 159 (49.4)
Missing 11 (2.1) 0 (0.0)
Age at assessment (y)
7-y assessment — 7.0 (7.0, 7.1)
Language of assessment —
English — 106 (33.8)
Spanish — 208 (66.2)
HOME Score Assessment 0.1 (−0:6–0:8)
Missing (n)b — —
Note:—, no data; CES-D, Center for Epidemiologic Studies Depression Scale; n, number of study participants; PPVT, Peabody Picture Vocabulary Test.
aAt age 7, a total of 322 mothers and 314 youth completed at least one neurodevelopmental assessment.
bMissing data for children followed-up were imputed with values collected on these variables at earlier or later time points for all analyses.
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metabolites from eight parent compounds: monoethyl phthalate
[MEP, metabolite of diethyl phthalate (DEP)]; mono-n-butyl
phthalate [MBP, metabolite of di-n-butyl phthalate (DnBP)];
monoisobutyl phthalate [MiBP, metabolite of diisobutyl phthalate
(DiBP)]; monobenzyl phthalate [MBzP, metabolite of butylbenzyl
phthalate (BBzP)]; four metabolites of di(2-ethylhexyl) phthalate
(DEHP): [mono(2-ethylhexyl) phthalate (MEHP), mono (2-ethyl-
5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl)
phthalate (MEOHP), and mono(2-ethyl-5-carboxypentyl) phthal-
ate (MECCP)]; mono(carboxyoctyl) phthalate [MCOP, metabolite
of diisononyl phthalate (DiNP)]; mono(carboxynonyl) phthalate
[MCNP, metabolite of diisodecyl phthalate (DiDP)]; and mono-3-
carboxypropyl phthalate (MCPP, metabolite of several HMW
phthalates and a minor metabolite of DBP). Quality control proce-
dures included the use of laboratory, calibration standards, and
quality controls of high and low concentrations. Limits of detection
(LODs) ranged from 0.2 to 0:6 ng=mL for individual metabolites.
Covariate Data Collection
Study staff administered structured questionnaires to mothers at
each study visit to collect information on a variety of factors,
including maternal and child demographics; maternal parity; pre-
natal diet and smoking, alcohol and illicit drug use; mode of deliv-
ery; duration of breastfeeding; parental marital status, maternal
education, and employment; and household income. We adminis-
tered the Peabody Picture Vocabulary Test (PPVT)-Revised
(Dunn and Dunn 1981) to estimate maternal receptive vocabulary
(6-month and 9-y study visits), the Center for Epidemiologic
Studies Depression Scale (CES-D) (Radloff 1977) to assess
maternal depression (1-, 3-, 7-, and 9-y visits), and the Home
Observation for the Measurement of the Environment-Short
Form (HOME-SF) (Caldwell and Bradley 1984) to assess enrich-
ment in the home (6-month, 1-, 2-, 3.5-, 7-, 9-, and 10.5-y visits).
We abstracted medical information, such as birth weight and ges-
tational duration, from prenatal and delivery medical records.
We examined potential confounding by other prenatal exposures
for which we have reported associations with adverse neurodevel-
opment in CHAMACOS, including organophosphate pesticides
(OPs) (Bouchard et al. 2011; Eskenazi et al. 2007; Marks et al.
2010), organochlorines (OCs) (Eskenazi et al. 2006; Gaspar et al.
2015), polybrominated diphenyl ether flame retardants (PBDEs)
(Eskenazi et al. 2013; Sagiv et al. 2015), and manganese (Mn)
(Mora et al. 2015). Detailed methods for prenatal biospecimen col-
lection and quantification of these chemicals have been described
previously (Bradman et al. 2005;Eskenazi et al. 2006;Eskenazi et al.
2013; Mora et al. 2015). Briefly, we quantified prenatal urinary dia-
lkyl phosphate (DAP)metabolite concentrations as ameasure of OP
exposure in the same two maternal pregnancy urine samples we
used to measure phthalate metabolites (collected at 13 and 26 wk
gestation) (Bradman et al. 2005). We also measured OCs (Eskenazi
et al. 2006) and PBDEs (Eskenazi et al. 2013) in pregnancy
[mean± standard deviation ðSDÞ=26:7±2:6 weeks] serum sam-
ples, or in maternal delivery samples for a subset of women
(∼ 10%) without pregnancy samples. We assessed prenatal expo-
sure toMn in children’s deciduous teeth (Mora et al. 2015).
Statistical Analysis
We averaged phthalate biomarker concentrations across the two
urine samples to better estimate exposure throughout pregnancy
(Hoppin et al. 2002) and log2-transformed to normalize the resid-
uals and reduce the influence of the outliers. For concentrations
below the LOD, we used the instrumental reading value, when
available, and imputed nondetectable concentrations (without an
instrumental reading) using maximum likelihood estimation fol-
lowing the log-normal distribution (Lubin et al. 2004).
We categorized phthalate metabolites based on their similarity
in chemical structure and biological activity (Teitelbaum et al.
2008) as: a) molar sums of metabolites of LMW (RLMW) phtha-
lates (i.e., MEP, MBP, and MiBP) or of metabolites of HMW
phthalates (RHMW) (i.e., MBzP, MCPP, MCOP, and MCNP);
and b) the molar sum of DEHP metabolites (RDEHP; i.e., MEHP,
MEHHP, MEOHP, and MECPP). We also looked at individual
phthalate metabolites (n=11).
We examined associations of average prenatal urinary phthalate
biomarker concentrations (individual metabolites and summed con-
centrations) with neurodevelopmental outcomes assessed at a single
time point (i.e., SRS, ENI, NEPSY-II, BASC-2 teacher-report,
CADS teacher-report, and SRP internalizing scale) using multivari-
able linear regression and at multiple time points (i.e., WCST,
BRIEF, WISC-IV, CADS, CPT-II, and other BASC-2 scales) using
Table 2. Distribution of phthalate biomarker concentrations (specific-gravity-corrected) measured in maternal urine samples collected at two time points during
pregnancy, CHAMACOS (n=327).
Phthalate biomarkera
% >LOD
r2btw
d r2within
d ICCd
Average of two measurements
1st measurementb 2nd measurementc GM (GSD) Min P25 P50 P75 Max
RLMW N/A N/A 0.94 2.14 0.31 1.5 (32.9) 0.1 0.7 1.4 2.9 105.7
MEP 100.0 99.7 1.26 2.59 0.33 241.7 (3.3) 14.3 108.5 223.1 501.9 20,462.0
MBP 98.8 100.0 0.30 2.29 0.11 28.4 (2.4) 1.3 16.2 26.8 47.6 529.8
MiBP 92.9 96.1 0.65 2.79 0.19 3.4 (2.7) 0.1 1.8 3.3 6.7 138.0
RHMW N/A N/A 0.34 1.27 0.21 0.3 (2.1) 0.0 0.2 0.3 0.5 5.1
MBzP 98.5 98.7 0.88 2.01 0.31 8.9 (2.6) 0.5 4.9 9.0 17.7 137.0
MCPP 88.3 93.6 0.62 3.02 0.17 2.2 (2.3) 0.0 1.4 2.4 3.8 28.5
MCOP 96.9 96.5 0.40 1.83 0.18 3.8 (2.1) 0.2 2.4 3.8 5.6 93.2
MCNP 95.7 96.8 0.43 1.46 0.23 2.3 (2.0) 0.2 1.5 2.3 3.4 42.7
RDEHP N/A N/A 0.38 1.43 0.21 0.2 (2.2) 0.0 0.1 0.2 0.4 5.0
MEHP 88.6 92.0 0.59 2.80 0.17 4.5 (2.6) 0.2 2.6 4.4 7.7 141.3
MEHHP 100.0 99.0 0.49 1.82 0.21 18.9 (2.4) 0.9 11.3 17.9 32.6 458.4
MECPP 100.0 100.0 0.36 1.29 0.22 32.4 (2.2) 4.2 20.9 31.4 49.6 631.8
MEOHP 98.2 98.7 0.52 2.10 0.20 13.8 (2.4) 0.6 8.1 14.0 22.4 335.0
Note: ICC, intraclass correlation coefficient; LOD, limit of detection; MBP, mono-n-butyl phthalate; MBzP, monobenzyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MCOP,
mono(carboxyoctyl) phthalate; MCNP, mono(carboxynonyl) phthalate; MECCP, mono(2-ethyl-5-carboxypentyl) phthalate; MEHP, mono-2-ethylhexyl phthalate; MEHHP, mono(2-
ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate; RDEHP, sum of di-2-ethylhexyl phthal-
ate metabolites; RHMW, sum of high-molecular-weight phthalate metabolites; RLMW, sum of low-molecular-weight phthalate metabolites.
aUnits are ng/mL for all individual metabolites and nmol/mL for the sums of metabolites (RDEHP, RHMW, RLMW).
bMedian (range) gestational age at urine collection= 12:9 (5.3–28.5) weeks gestation.
cMedian (range) gestational age at urine collection= 26:3 (21.8–39.5) weeks gestation.
dVariances between- and within-woman and ICC were calculated and reported for log2-transformed specific-gravity adjusted urinary phthalate concentrations (nonaveraged).
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generalized estimating equations (GEE). If associations of phthalates
with repeated measures of an outcome changed appreciably over
time, we presented estimates from the linear regression analyses for
each time point separately. To evaluate the presence of nonlinearity in
exposure–outcome associations, we modeled phthalate concentra-
tions categorized into tertiles.
We selected the following covariates a priori using a directed
acyclic graph (See Figure S1):maternal age at enrollment (continu-
ous), education (categorical: <6th grade, 7th–12th grade, com-
pleted high school), country of birth (categorical: Mexico vs.
other), years in the United States (continuous), and depression sta-
tus at the time of assessment (dichotomous: <16 vs. ≥16 points in
CES-D); child sex (dichotomous) and exact age at assessment
(continuous); language of assessment or language of interview for
parent-reported outcomes (dichotomous); HOME z-score at time
of assessment (continuous); household income at the time of
assessment (categorical: at or below poverty line vs. above poverty
line); and psychometrician. Because the CPT-II and WCST were
computerized tasks, we additionally adjusted these outcomes for
children’s video game usage (average hours per week) at age 9 as
reported bymothers.We imputedmissing values for covariates (all
<10% missing) using data from the nearest available visit. If val-
ues for a missing covariate were not available from an earlier or
later study visit, we randomly selected a value from the dataset
(n=1 participant missing HOME score and maternal depression
values at the 14- and 16-y visits; n=2 participants missing mater-
nal PPVT for sensitivity analyses).
We evaluated effect modification of the exposure–outcome
associations by child sex using an augmented product term
approach (Buckley et al. 2017) in which we specified a model
including product terms between sex and each of the covariates,
including sex. Interactions were assessed using sex-metabolite
product terms from the same model and were considered statisti-
cally significant if p<0:10.
We conducted sensitivity analyses to assess the robustness
of our results. First, we fitted our regression models excluding
preterm births (n=27; defined as delivery <37weeks) and low
birth weight (LBW) children (n=14; defined as birthweight
<2,500 grams) (n=11 LBW and preterm). The number of chil-
dren excluded varied by neurodevelopmental test because not
all study participants completed each test. Second, we adjusted
our regression models for additional potential confounders [i.e.,
breastfeeding duration (<6months vs. ≥6months) and maternal
receptive vocabulary at the 9-y visit (PPVT score: ≤74, 75–99,
≥100) by adding them individually to models. Last, we examined
the confounding effects of prenatal exposure to other known neuro-
toxicants by adding prenatal PBDEs, DAPs, OCs, and Mn concen-
trations individually to our adjusted models. These additional
neurotoxicants were modeled continuously and log-transformed
(PBDEs, DAPs, and OCs transformed to the log10 scale and Mn
transformed to the log2 scale). PBDEs were modeled as the lipid-
adjusted sum of four congeners (−47, −99, −100, −153), and
OCs were modeled as the lipid-adjusted sum of dichlorodiphenyl-
trichloroethane (p,p0-DDT, o,p0-DDT), and dichlorodiphenyldi-
chloroethylene (p,p0-DDE) from maternal serum collected at 26
wk gestation. Total DAP metabolite levels were calculated as the
sum of six nonspecific urinary OP metabolites, averaged across
two prenatal urine samples. All levels below the LOD were set at
LOD
ffiffiffi
2.
Results
Table 1 shows the sociodemographic characteristics of mother–
child pairs from the initial cohort who delivered a live-born single-
ton (n=527) and participants with prenatal phthalate data who
completed at least one neurodevelopmental test at age 7 y
(n=322). Table S1 shows the sociodemographic characteristics of
participants with prenatal phthalate data who completed at least
one neurodevelopmental test at age 9, 10.5, 12, 14, or 16 y. Among
those with at least one neurodevelopmental assessment at age 7 y,
most mothers were born in Mexico (86%), had not completed high
school (78%), and had a family income below the U.S. poverty
threshold (70%) (Table 1). Nearly 53% of CHAMACOS children
were female, and 49%were breastfed for >6months (Table 1). The
standardized scores for each neurodevelopmental test are shown in
Table S2.
Phthalate metabolites were detected in 88%–100% of sam-
ples, depending on the metabolite (Table 2). Phthalate metabolite
concentrations were generally similar to those measured in
NHANES participants around the same time period (CDC 2018)
(see Table S3 for uncorrected phthalate metabolite concentra-
tions). Between-person variance exceeded within-person var-
iance by a factor of two to eight (Table 2). Intraclass correlation
coefficients (ICC) varied from 0.11 to 0.33 (Table 2). Spearman’s
correlation coefficients among different phthalate metabolites
ranged from 0.11 to 0.98 (see Table S4).
Our analysis of tertiles provided evidence of nonlinearity for
some associations, such as for RLMW and RDEHP with WCST
executive function outcomes (see Table S5). However, given
that most exposure–outcome associations were linear (see
Tables S5–S11), we included phthalate biomarker concentra-
tions parameterized as continuous variables in all models, with
point estimates representing the change in outcome for each 2-
fold increase in biomarker concentrations. In our main analyses,
we present results for the phthalate biomarkers RLMW, RHMW,
and RDEHP. Results for individual phthalate metabolites are
included in SupplementaryMaterial.
Executive Function
Most associations between prenatal concentrations of RLMW,
RHMW, and RDEHP with executive function outcomes were null
in both combined (Table 3) and sex-stratified (see Table S12) analy-
ses. When stratified by sex, we found that higher prenatal RLMW
concentrations were associated with better scores for perseverative
errors among boys (b=1:4, 95% CI: 0.3, 2.5), but not among girls
(b=0:1, 95% CI: −0:9, 1.1; p-int = 0:08; see Table S12).
Cognition
We found mostly null associations of prenatal RLMW, RHMW,
and RDEHP concentrations with IQ scores in analyses of boys
and girls combined (Table 3). However, when we stratified by
child’s sex, we observed that higher prenatal RHMW concentra-
tions were associated with lower FSIQ (b= − 1:9, 95% CI: −4:1,
0.3) and WMIQ (b= − 2:1, 95% CI: −4:2, 0.0) scores among
boys but higher FSIQ, WMIQ, and PSIQ scores among girls
(b=1:8, 95% CI: 0.1, 3.3; b=1:8, 95% CI: 0.1, 3.4; and b=1:5,
95% CI: 0.2, 2.9; respectively; all p-int <0:10; see Figure 1 and
Table S12). Similarly, higher RDEHP concentrations were asso-
ciated with decreased WMIQ scores in boys (b= − 1:9, 95% CI:
−3:9, 0.1) and increased FSIQ, WMIQ, and PSIQ scores among
girls (b=1:6, 95% CI: 0.0, 3.2; b=1:6, 95% CI: 0.1, 3.2; and
b=1:5, 95% CI: 0.1, 2.8; respectively; all p-int <0:10; see Figure 1
and Table S12). Among all children, MEP concentrations were
associated with slightly decreased WMIQ scores (b= − 0:6, 95%
CI: −1:3, 0.1) and MiBP concentrations were associated with
slightly increased PSIQ scores (b=0:9, 95% CI: 0.0, 1.8; see
Table S13). Effect estimates for VCIQ were null for all metabolites
in both stratified and sex-stratified analyses (Table 3, Table S12,
Table S13).
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Social Cognition
Most associations of prenatal phthalate concentrations with social
cognition outcomes hovered at the null in both combined and
sex-stratified analyses. Higher RDEHP concentrations were asso-
ciated with slightly better scores on the ENI assessment at 9 y
among all children (b=0:1, 95% CI: 0.0, 0.2; see Table 4) and
among girls (b=0:2, 95% CI: 0.0, 0.4; see Table S14).
Behavior
Among all children, higher prenatal RLMW phthalate concentra-
tions were associated with more errors of omission (higher T-
scores) on the performance-based CPT-II (b=0:9; 95% CI: 0.0,
1.8) measured at 9 and 12 y (Table 4) and poorer self-reported
behaviors measured using the BASC-2 SRP scale, including
more hyperactivity (b=0:8; 95% CI: 0.1, 1.4), attention problems
(b=1:5; 95% CI: 0.7, 2.2), anxiety (b=0:9; 95% CI: 0.0, 1.8),
and overall internalizing problems on the composite scale
(b=1:2; 95% CI: 0.4, 1.9) measured at 16 y (Table 5). Similar,
albeit weaker, trends were observed for parent-reported BASC-2
results modeled using GE; however, associations of phthalates
with most teacher-reported behaviors were null or in the opposite
direction of parent- and self-reported results (Table 4). We did
not observe consistent sex-specific associations for behavior out-
comes in GEE (Table S14) or linear regression models (Table
S15). Prenatal MEP, MBzP, MCPP, and MCOP concentrations
were associated with increased scores for parent-reported inter-
nalizing problems and/or errors of commission (Table S16).
Similarly, prenatal concentrations of MEP and MCPP were asso-
ciated with increased self-reported internalizing problems at age
16 (Table S17).
Sensitivity Analyses
In general, the point estimates did not change appreciably in sen-
sitivity analyses after a) excluding preterm births and LBW chil-
dren (see Tables S18–S20), and b) adjusting for additional
potential confounders, including maternal receptive vocabulary
(see Tables S21–S23) and breastfeeding duration (see Tables
S24–S26). Associations of prenatal RLMW phthalate concentra-
tions with self-reported hyperactivity, depression, and anxiety
were attenuated in models adjusted for coexposure to PBDEs
(Tables S27–S29), OP and OC pesticides (Tables S30–S35), and
Mn (Tables S36-38), with all CI including the null.
Discussion
In this prospective cohort of low-income Mexican-American
children, we observed primarily null associations of prenatal uri-
nary phthalate biomarker concentrations with a wide range of
measures of childhood and adolescent cognition and behavior.
We did find suggestive associations of prenatal RLMW phtha-
lates with more parent- and self-reported internalizing problems
and poorer scores on performance-based behavioral assessments
(i.e., CPT-II errors of omission). We also observed that prenatal
RHMW and RDEHP concentrations were associated with slightly
higher IQ scores among girls and lower IQ scores among boys.
The previous literature from longitudinal birth cohort studies
evaluating prenatal phthalate exposure and childhood neurodevel-
opment has produced mixed results. With respect to cognitive func-
tion, the Columbia Center for Children’s Environmental Health
(CCCEH) study reported that prenatal concentrations of the LMW
phthalate metabolites MBzP and MiBP were inversely associated
with IQ scores among 328 children age 7 y (Factor-Litvak et al.
2014). Conversely, the Health Outcomes and Measures of the
Environment (HOME) study found that higher prenatal concentra-
tions of LMW phthalate metabolites, including MBzP and MBP,
were associated with improved performance on the Virtual Morris
Water Maze among 198 8-y-old children, particularly among boys
(Braun et al. 2017). We also found evidence of better cognition in
association with higher prenatal phthalate exposure in sex-stratified
analyses in CHAMACOS; however, we observed that prenatal
RHMW and RDEHP concentrations were associated with slightly
higher IQ scores among girls and lower IQ scores among boys.
Only one previous study, the Mount Sinai Children’s
Environmental Healthy study, examined associations of prenatal
phthalate exposure with executive function and found that higher
RLMW metabolite concentrations from third-trimester maternal
Table 3. Adjusted associations [b (95% CI)] of prenatal urinary phthalate biomarker concentrations (nmol/mL; log2-transformed and specific gravity-adjusted)
a
with executive function and cognition outcomes at 7, 9, 10.5, and/or 12 y using GEE models, CHAMACOS.
Outcomes Orientationb n k RLMW RHMW RDEHP
Executive function
WCST (T-score) (9, 12 y)
Errors (−) 593 318 0.2 (−0:4, 0.8) 0.5 (−0:4, 1.4) 0.5 (−0:3, 1.3)
Perseverative Errors (−) 593 318 0.7 (−0:1, 1.4) 0.7 (−0:6, 1.9) 0.6 (−0:5, 1.8)
BRIEF—parent report (T-score) (7, 9, 12 y)
Behavioral Regulation Index ( + ) 923 331 0.1 (−0:5, 0.6) 0.1 (−0:8, 1.0) 0.0 (−0:9, 0.8)
Metacognition Index ( + ) 922 330 −0:4 (−1:0, 0.1) −0:1 (−1:0, 0.9) −0:1 (−1:0, 0.7)
Global Executive Composite ( + ) 923 331 −0:3 (−0:8, 0.3) 0.0 (−1:0, 1.0) −0:1 (−1:0, 0.8)
NEPSY Tower (scaled score)c (9 y) (−) 313 313 0.1 (−0:1, 0.3) 0.1 (−0:2, 0.4) 0.1 (−0:2, 0.4)
Cognitiond
WISC-IV Full-Scale IQ (scaled scores) (7, 10.5 y) (−) 589 321 −0:2 (−1:0, 0.6) 0.0 (−1:4, 1.4) 0.1 (−1:3, 1.4)
Verbal comprehension IQ (−) 621 324 −0:4 (−1:1, 0.4) −0:3 (−1:6, 1.0) −0:3 (−1:5, 1.0)
Perceptual reasoning IQ (−) 621 324 0.2 (−0:7, 1.2) 0.4 (−1:1, 1.9) 0.3 (−1:1, 1.7)
Working memory IQ (−) 593 323 −0:6 (−1:4, 0.1) −0:1 (−1:5, 1.2) −0:1 (−1:4, 1.2)
Processing speed IQ (−) 593 323 0.2 (−0:4, 0.9) 0.5 (−0:7, 1.7) 0.5 (−0:6, 1.7)
Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment; child sex, child age at time of assessment,
language of assessment, HOME score, and household income at time of assessment. WCST models were also adjusted for children’s video game usage. BRIEF, Behavior Rating
Inventory Executive Function; k, number of children with data for at least one time point; n, number of observations from all time points; NEPSY, A Developmental
Neuropsychological Assessment; RLMW, sum of metabolites of low-molecular-weight phthalates; RHMW, sum of metabolites of high-molecular-weight phthalates; RDEHP, sum of di
(2-ethylhexyl) phthalate metabolites; WCST, Wisconsin Card Sort Task-64: computer version 2—research edition; WISC-IV, Wechsler Intelligence Scale for Children 4th edition.
aSeparate models created for each sum of metabolites (RDEHP, RHMW, RLMW).
b( + ) Higher scores indicate poorer performance/more symptomatic behavior; (−) lower scores indicate poorer performance/more symptomatic behavior.
cNEPSY tower measured at one time point and modeled using linear regression.
dData also presented in Figure 1.
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Figure 1. Adjusted associations [b (95% CI)] for WISC-IV IQ scores per 2-fold increase in prenatal (A) RLMW, (B) RHMW, and (C) RDEHP concentrations
(nmol/mL; log2-transformed and specific gravity-adjusted) among all children and stratified by sex using GEE models. Models adjusted for maternal age at
enrollment, education, country of birth, years in the United States, depression at time of assessment; child sex, child age at time of assessment, language of
assessment, HOME score, and household income at time of assessment. Sex-specific effect estimates and p-int values obtained from models including cross-
product terms between child sex and the exposure and child sex and each of the covariates. p-int represents interaction of exposure and sex obtained from these
models. Data also shown in Tables 3 and S12.
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urine were associated with poorer BRIEF global executive com-
posite index scores in 188 children ages 4–9 y (Engel et al.
2010). In contrast, we found null associations for phthalates and
BRIEF behavioral regulation and global executive composite
scores, and slightly better scores on the parent-reported BRIEF
metacognition index.
Three previous studies have reported associations of prenatal
phthalates with more externalizing behaviors, including aggression,
hyperactivity, and conduct problems (Engel et al. 2010; Kobrosly
et al. 2014; Lien et al. 2015). TheMount Sinai study reported associ-
ations of prenatal LMW phthalate concentrations with parent report
of increased aggression, attention, and conduct problems on the
BASC among children ages 4–9 y (Engel et al. 2010). A study of
122mother–child pairs inTaiwan found that prenatal concentrations
of LMW phthalate metabolites, as well as DEHP metabolites, were
associated with parent report of more aggressive and delinquent
behaviors on the Child Behavior Checklist (CBCL) at 8 y (Lien et al.
2015). In the multicenter Study for Future Families of 153 children
ages 6 to 10 y in 4 U.S. states, prenatal MBP, a LMW phthalate, was
associated with more parent-reported inattention, rule-breaking
behavior, aggression, and conduct problems on the CBCL (Kobrosly
et al. 2014). In addition, prenatalMBzP, aHMWphthalate, was asso-
ciated with more parent-reported oppositional and conduct problems,
but only among boys (Kobrosly et al. 2014). Only the Spanish
INfancia y Medio Ambiente (INMA)-Sabadell birth cohort study
(n=367) found essentially null associations for prenatal phthalate
biomarkers and all behavioral outcomes, including ADHD-related
behaviors, measured at 4 and 7 y (Gascon et al. 2015). In the
CHAMACOS study, we observed modest associations of RLMW
phthalates with attention problems, including poorer performance on
the CPT-II at ages 9 and 12 and more symptomatic self-reported
BASC-2 hyperactivity and attention problems scores at age 16.
Associations with all other externalizing behaviors, including those
from teacher-, parent-, and self-report, were essentially null.
Results from previous studies are less consistent with respect to
internalizing behaviors. Although the Mount Sinai study reported
associations of prenatal RLMW phthalate concentrations with
more anxiety and depression among all children (Engel et al.
2010), the Study for Future Families found associations with less
anxiety among girls (Kobrosly et al. 2014), and the Taiwanese
study reported null associations for prenatal phthalates with all
internalizing behaviors (Lien et al. 2015). Furthermore, the
CCCEH study reported associations of prenatal MBP and MBzP
concentrations (metabolites of LMW phthalates) with more inter-
nalizing behaviors among all children, with stronger associations
observed for MBzP among girls (Whyatt et al. 2012). Associations
Table 4. Adjusted associations [b (95% CI)] of prenatal urinary phthalate biomarker concentrations (nmol/mL; log2-transformed and specific gravity-adjusted)
a
with behavior and social cognition outcomes at 7, 9, 10.5, 12, 14, and/or 16 y using GEE models, CHAMACOS.
Outcomes Orientationb n k RLMW RHMW RDEHP
Social cognitionc
SRS Total Score (14 y) ( + ) 245 245 0.4 (−0:2, 0.9) −0:3 (−1:1, 0.5) −0:3 (−1:1, 0.5)
ENI (9 y) (−) 313 313 0.0 (−0:1, 0.1) 0.1 (−0:1, 0.2) 0.1 (0.0, 0.2)
NEPSY-II (12 y) (−) 310 310 −0:1 (−0:3, 0.2) −0:3 (−0:7, 0.1) −0:2 (−0:5, 0.2)
Behavior
BASC-2—parent-report (T-score)
Internalizing problems (7, 10.5, 14, 16 y) ( + ) 1,226 328 0.4 (−0:1, 1.0) 0.5 (−0:4, 1.4) 0.4 (−0:5,1.2)
Depression scalec (7 y) ( + ) 322 322 0.4 (−0:1, 1.0) 0.4 (−0:5, 1.3) 0.3 (−0:6, 1.1)
Anxiety scalec (7 y) ( + ) 313 313 0.3 (−0:3, 1.0) 0.8 (−0:4, 1.9) 0.6 (−0:5, 1.7)
Externalizing problems (7, 10.5, 14, 16 y) ( + ) 1,219 328 0.1 (−0:4, 0.5) 0.2 (−0:6, 0.9) 0.1 (−0:6, 0.7)
Hyperactivity scale (7, 10.5, 14, 16 y) ( + ) 1,226 328 0.0 (−0:4, 0.4) −0:1 (−0:7, 0.6) −0:1 (−0:8, 0.5)
Attention problems scale (7, 10.5, 14, 16 y) ( + ) 1,226 328 0.0 (−0:5, 0.5) −0:1 (−1:0, 0.7) −0:1 (−0:9, 0.7)
BASC-2—teacher-report (T-score)c
Internalizing problems (7 y) ( + ) 265 265 −0:7 (−1:6, 0.2) −0:4 (−1:8, 1.0) −0:3 (−1:6, 1.0)
Depression scale (7 y) ( + ) 265 265 −0:6 (−1:4, 0.1) −0:2 (−1:4, 0.9) −0:2 (−1:4, 0.9)
Anxiety scale (7 y) ( + ) 265 265 −0:9 (−1:8, 0.1) −0:8 (−2:1, 0.5) −0:7 (−2:0, 0.6)
Externalizing problems (7 y) ( + ) 265 265 −0:1 (−0:8, 0.6) 0.0 (−1:0, 1.0) 0.2 (−0:7, 1.1)
Hyperactivity scale (7 y) ( + ) 265 265 0.0 (−0:7, 0.7) −0:2 (−1:4, 0.9) −0:1 (−1:1, 0.9)
Attention problems scale (7 y) ( + ) 265 265 0.2 (−0:8, 0.4) −0:5 (−1:4, 0.4) −0:3 (−1:2, 0.5)
CADS—parent-report (T-score)
ADHD Index (7, 9, 12 y) ( + ) 920 332 −0:3 (−0:7, 0.1) −0:2 (−1:0, 0.5) −0:2 (−1:0, 0.5)
DSM-IV Total Scale (7, 9, 12 y) ( + ) 921 332 −0:3 (−0:7, 0.1) −0:1 (−1:0, 0.7) −0:2 (−1:0, 0.5)
Inattentive scale (7, 9, 12 y) ( + ) 920 332 −0:3 (−0:7, 0.1) −0:3 (−1:0, 0.5) −0:3 (−0:9, 0.4)
Hyperactive/impulsive scale (7, 9, 12 y) ( + ) 920 332 −0:2 (−0:7, 0.2) 0.0 (−0:9, 0.9) −0:1 (−1:0, 0.7)
CADS—teacher-report (T-score)c
ADHD Index (7 y) ( + ) 261 261 −0:4 (−1:2, 0.5) −0:5 (−1:9, 0.9) −0:4 (−1:6, 0.9)
DSM-IV Total Scale (7 y) ( + ) 260 260 −0:2 (−0:9, 0.5) −0:2 (−1:4, 1.0) −0:1 (−1:2, 1.0)
Inattentive scale (7 y) ( + ) 264 264 −0:1 (−0:8, 0.5) −0:1 (−1:2, 0.9) −0:1 (−1:0, 0.9)
Hyperactive/impulsive scale (7 y) ( + ) 264 264 −0:1 (−0:8, 0.6) 0.1 (−1:1, 1.3) 0.2 (−0:9, 1.3)
CPT-II (T-score)
Errors of omission (9, 12 y) ( + ) 595 317 0.9 (0.0, 1.8) −0:1 (−1:2, 1.1) −0:2 (−1:2, 0.9)
Errors of commission (9, 12 y) ( + ) 595 317 0.3 (−0:2, 0.8) −0:1 (−1:0, 0.8) −0:3 (−1:1, 0.6)
ADHD confidence index (9, 12 y) ( + ) 596 317 0.7 (−0:5, 1.9) −1:0 (−2:7, 0.8) −1:0 (−2:6, 0.6)
Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment; child sex, child age at time of assessment,
language of assessment, HOME score, and household income at time of assessment. CPT-II models were also adjusted for children’s video game usage at time of assessment. ADHD,
Attention Deficit Hyperactivity Disorder; BASC-2, Behavior Assessment System for Children, 2nd edition; CADS, Conners' ADHD/DSM-IV Scales; CPT-II, Continuous
Performance Test, 2nd edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ENI, Evaluación Neuropsicológica del Niño; k, number of children with
data for at least one time point; n, number of observations from all time points; NEPSY-II, A Developmental Neuropsychological Assessment, 2nd Edition; RLMW, sum of metabo-
lites of low-molecular-weight phthalates; RHMW, sum of metabolites of high-molecular-weight phthalates; RDEHP, sum of di(2-ethylhexyl) phthalate metabolites. SRS, Social
Responsiveness Scale, version 2.
aSeparate models created for each sum of metabolites (RDEHP, RHMW, RLMW).
b( + ) Higher scores indicate poorer performance/more symptomatic behavior; (−) lower scores indicate poorer performance/more symptomatic behavior.
cMeasured at one time point and modeled using linear regression.
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of prenatal RLMW phthalates and BASC self-report of internaliz-
ing behaviors at age 16 were among the strongest in the
CHAMACOS study, though associations with BASC parent report
were considerably weaker, and BASC teacher-report associations
were in the opposite direction. Although these results may seem
paradoxical, they are largely in line with previous studies that have
reported poor multiple informant agreement for parent-, teacher-,
and child-reported behaviors, with worse concordance among par-
ticipants with internalizing disorders (Miller et al. 2014; Verhulst
and Akkerhuis 1989). Although externalizing problems may be
more easily observed by others, a child can choose not to disclose
feelings of anxiety or depression to teachers or caregivers
(Salbach-Andrae et al. 2009). Previous studies indicate that
teacher–youth agreement may be less than parent–youth agree-
ment (Youngstrom et al. 2000), particularly for internalizing disor-
ders (Salbach-Andrae et al. 2009), which is largely consistent with
findings from our study. We observed the strongest findings for
self-reported behavior at age 16, and evidence suggests that dis-
crepancies in parent- and self-report and the reliability of self-
reported behaviors increase with age (Edelbrock et al. 1985;
Verhulst and Akkerhuis 1989). Although reports from multiple
informants provide a more comprehensive picture of behaviors of
children and adolescents throughout time, adolescents may be a
more reliable source about their own internalizing behavior.
Consistent with the results from a study of 201 children age
3 y from the Markers of Autism Risk in Babies—Learning
Early Signs (MARBLES) cohort (Shin et al. 2018), a study of
175 children ages 4–5 y from the HOME cohort (Braun et al.
2014), and the Spanish INMA-Sabadell birth cohort (Gascon
et al. 2015), we found null associations of prenatal phthalate
exposure with social cognition outcomes. In contrast, a study of
137 children ages 7–9 y from the Mount Sinai cohort found that
higher prenatal RLMW phthalate concentrations were associated
with poorer SRS scores (Miodovnik et al. 2011). To our knowledge,
ours is the first study to investigate phthalate-related associations
with tests of affect recognition (i.e., ENI and NEPSY-II), which
may provide more comprehensive and objective data than parent-
report alone.
Potential reasons for the heterogeneity in our findings and those
from previous studies include differences in a) sample size, b) timing
and number of prenatal exposuremeasurements, c) specific phthalate
metabolites measured, d) neurodevelopmental tests administered, e)
age of child at neurodevelopmental assessments, and f) sociodemo-
graphic characteristics that may influence phthalate exposure. For
example, we assessed a larger diversity of neurodevelopmental out-
comes than many previous studies assessed, and ours is the only
study to examine associations of prenatal phthalates exposure with
behavior and executive function using computer-based assessments.
Additionally,we had a larger sample size than those in someprevious
investigations and assessed phthalate exposure from two prenatal
urine samples, whereas many previous studies relied on one mea-
surement. Notably, some of our strongest findings were for self-
reported behavioral outcomes at age 16, and to our knowledge, ours
is the first study to examine associations of prenatal phthalate expo-
sure and neurodevelopment past age 10 y.
Our study has several strengths and limitations. The longitudinal
design of CHAMACOS and collection of rich data, including bio-
logical specimens, a wide array of neurodevelopmental measures,
behavioral measures frommultiple reporters (e.g., parents, teachers,
and participants), and covariates, allowed for a very thorough and
nuanced examination of the potential impacts of in utero phthalate
exposure throughout childhood and adolescence. Ours is the first
study to our knowledge to investigate the impacts of prenatal phthal-
ate exposure and neurocognitive outcomes during adolescence,
allowing us to examine the persistence of effects identified in cohorts
of younger children. In addition, although previous studies have
relied solely on parent-report of executive function, behavior, and
social cognition, we directly assessed participants with respect to ex-
ecutive function (WCST and NEPSY Tower), attention and impulse
control (CPT-II), and social cognition (ENI and NEPSY Affect
Recognition). These arguably more objective, performance-based
tests contribute to the richness of our neurodevelopmental assess-
ments. Furthermore, to our knowledge, we are the first longitudinal
study to examine the effects of prenatal phthalate exposure on ado-
lescent self-reported behavior, which may provide more nuanced in-
formation on internalizing behaviors such as anxiety and depression.
Table 5. Adjusted associations [b (95% CI)] of prenatal urinary phthalate biomarker concentrations (nmol/mL; log2-transformed and specific gravity-adjusted)
a
with self-reported BASC-2 behavioral outcomes at 10.5, 14, and 16 y using linear regression models, CHAMACOS.
Outcome Orientationb n RLMW RHMW RDEHP
10.5-y assessment
Internalizing problems (+ ) — — — —
Depression scale ( + ) 289 0.5 (−0:1, 1.1) 0.7 (−0:5, 1.9) 0.6 (−0:5, 1.8)
Anxiety scale ( + ) 289 0.3 (−0:3, 1.0) 0.5 (−0:6, 1.5) 0.4 (−0:6, 1.4)
Externalizing problems
Hyperactivity scale ( + ) 299 0.2 (−0:5, 0.8) 0.5 (−0:6, 1.5) 0.3 (−0:7, 1.3)
Attention problems scale ( + ) 290 −0:1 (−0:8, 0.7) −0:4 (−1:5, 0.8) −0:4 (−1:4, 0.7)
14-y assessment
Internalizing problems (+ ) — — — —
Depression scale ( + ) 301 0.5 (−0:1, 1.2) 0.6 (−0:6, 1.8) 0.5 (−0:6, 1.6)
Anxiety scale ( + ) 300 0.4 (−0:2, 1.1) −0:3 (−1:3, 0.7) −0:4 (−1:3, 0.6)
Externalizing problems
Hyperactivity scale ( + ) — — — —
Attention problems scale ( + ) — — — —
16-y assessment
Internalizing problems (+ ) 283 1.2 (0.4, 1.9) 0.4 (−0:7, 1.4) 0.4 (−0:6, 1.3)
Depression scale ( + ) 286 0.7 (−0:1, 1.5) 0.2 (−0:8, 1.2) 0.3 (−0:7, 1.2)
Anxiety scale ( + ) 286 0.9 (0.0, 1.8) 0.7 (−0:4, 1.8) 0.6 (−0:5, 1.7)
Externalizing problems
Hyperactivity scale ( + ) 285 0.8 (0.1, 1.4) 0.0 (−1:0, 1.0) −0:2 (−1:2, 0.8)
Attention problems scale ( + ) 286 1.5 (0.7, 2.2) −0:2 (−1:2, 0.8) −0:3 (−1:2, 0.6)
Note: Models were adjusted for maternal age at enrollment, education, country of birth, years in the U.S., depression at time of assessment;—, no data; child sex, child age at time of
assessment, language of assessment, HOME score, and household income at time of assessment. BASC-2, Behavior Assessment System for Children, 2nd edition; n, number of chil-
dren; RLMW, sum of metabolites of low-molecular-weight phthalates; RHMW, sum of metabolites of high-molecular-weight phthalates; RDEHP, sum of di(2-ethylhexyl) phthalate
metabolites.
aSeparate models created for each sum of metabolites (RDEHP, RHMW, RLMW).
b( + ) Higher scores indicate poorer performance/more symptomatic behavior; (−) lower scores indicate poorer performance/more symptomatic behavior.
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Although the collection of rich neurodevelopmental data across
various domains is a primary strength of our study, it also makes
interpretation of our results more difficult, as demonstrated by
inconsistency in our findings across these multiple outcomes.
More important, we conducted a large number of analyses with
multiple comparisons, which could produce spurious associations
by chance alone. Therefore, we were careful to report patterns in
our results rather than highlighting isolated findings. Overall, the
richness and diversity of our outcomes allow us to conclude with
some confidence that prenatal exposure to select phthalates is not
strongly associated with neurodevelopment in our cohort.
The prenatal period has been identified as the most vulnerable
window of neurotoxicity (Lioy et al. 2015); however, emerging
evidence indicates that childhood phthalate exposure may be asso-
ciated with adverse cognitive outcomes among children ages 2 to
12 y (Cho et al. 2010; Factor-Litvak et al. 2014; Huang et al. 2015;
Kim et al. 2017; Li et al. 2019). We did not measure childhood
phthalate concentrations in our cohort, and it is possible that post-
natal exposures could affect neurodevelopment in this population,
particularly during puberty, a period during which the brain is
developing rapidly and may be particularly susceptible to EDCs
(Wang et al. 2016). Previous research has shown sex-specific
changes in internalizing and externalizing behaviors, executive
function, and social cognition during puberty (Blakemore et al.
2010; Gur and Gur 2016; Spear 2013), and a toxicology study
found that DEHP exposure during puberty was associated with
increased anxiety among female mice (Wang et al. 2016). In addi-
tion to prenatal exposures, future studies should consider also
assessing phthalate concentrations during childhood and adoles-
cence to identify critical periods of susceptibility.
Our study and others have shown relatively low correlation
between phthalate measurements collected at multiple times during
pregnancy (Gascon et al. 2015) and poor reproducibility between
measurements (Johns et al. 2015). Other studies have also suggested
that phthalate metabolite concentrations can vary depending on the
time of day at which the urine sample was collected (Silva et al.
2004) and that exposure biomarker patterns may vary, depending
on the primary source of phthalate exposure (Johns et al. 2015;
Preau et al. 2010). In addition to introducing nondifferential expo-
sure misclassification that may have biased our results toward the
null, the nonpersistent nature of phthalates makes it difficult to iden-
tify windows of susceptibility based on the timing of prenatal expo-
sure (Braun et al. 2014). Future research investigating these
exposure–outcome relationships should include a more critical eval-
uation of the most robust sampling strategy (Shin et al. 2019) (i.e.,
spot, first morning void, 24-h collection) to reduce exposure mea-
surement error for the phthalate metabolite of interest.
Overall, we found mostly null associations of prenatal phthal-
ate exposure with child and adolescent neurodevelopmental out-
comes in the CHAMACOS cohort, though we observed some
suggestive associations of prenatal LMWphthalate biomarker con-
centrations with more internalizing and externalizing behaviors,
particularly from self-reported and performance-based assess-
ments. These findings add to a growing literature addressing the
potential developmental neurotoxicity of phthalate exposure.
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